Subscribe
Funding & M&A
3 min read

Waypoint puts seed money into RxActuator's wearable infuser

RxActuator said on October 15th, 2026 that Waypoint Ventures anchored its seed round, amount undisclosed, to back the relaunch of its Mini-Infuser. The wearable pump lets vets send stable pets home on a 48-hour infusion.

Published on
October 16, 2026
Waypoint puts seed money into RxActuator's wearable infuser

RxActuator said on October 15th, 2026 that Waypoint Ventures has anchored its seed round, backing the relaunch of the Mini-Infuser, a wearable pump that delivers medication under a pet's skin for 48 hours. It did not disclose the amount.

The device lets a stable patient go home on a continuous-rate infusion instead of staying tethered to an IV pump in the clinic. Vets use it after surgery and for chronic pain, hospice care and antibiotics, the company says.

Waypoint is backing a product clinics already buy

RxActuator is the trade name of Journey Actuating Technologies, which bought the Mini-Infuser technology and related assets in early 2026 and relaunched the product under the RxActuator brand on October 1st. The company says more than 500 units have been used by over 90 veterinary clinics in three countries, with most volume from repeat accounts.

Founder and CEO Jeff Journey is a U.S. Air Force veteran. Waypoint's first fund leans toward leaders from the U.S. Service Academies.

General partner Jeff Walker said Journey "has taken a de-risked technology and given it the leadership, systems and commercial strategy it needed."

For scale, DeepScan raised $3.5M in April to grow its canine cfDNA test from a 100-clinic base. RxActuator is at a similar clinic count. It also has hardware to build.

The pitch to clinics is bed space and margin

The Mini-Infuser is sold only to clinics, and the storefront keeps clinic pricing behind a login. RxActuator's homepage argues that every pancreatitis patient in a cage for days is a bed that could have held a surgical case.

Its profit calculator, at default settings of an $800 daily hospitalization fee and five pancreatitis cases a month, returns $88,800 in new annual profit. That total includes "a $450 combined markup and oversight fee" per protocol.

The infuser is single use, so revenue repeats with every case. That is the model that carries vet diagnostics (consumables were 88% of point-of-care diagnostics revenue in the report we covered in May).

One small pilot carries the clinical case

RxActuator cites a 2025 Journal of Veterinary Internal Medicine pilot for an 89.5% outpatient success rate and costs about 60% to 70% below inpatient care. The study followed 19 dogs with pancreatitis, had no inpatient comparison group and was funded by CEVA Animal Health.

The company says the new money will expand manufacturing, push the device into new specialties and build infusion technology that links drug delivery to clinical outcomes. Data from a second specialty would give clinics more than one use case to buy for.

Source: RxActuator via EIN Presswire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Rover names Vik Rajagopal CFO and Jensen Harris president
People
3 min read

Rover names Vik Rajagopal CFO and Jensen Harris president

Rover named Vik Rajagopal chief financial officer and Jensen Harris president of marketplace, product and technology. Rajagopal succeeds Charlie Wickers, and Harris succeeds Brent Turner in the president role.

Read article
Read article
Fresh Step puts designer scents in litter, starting at Walmart.com
Launches
3 min read

Fresh Step puts designer scents in litter, starting at Walmart.com

Fresh Step launched Fleur de Purr, a 20 lb clumping litter in two designer-inspired scents with a $20 list price. It is sold exclusively on Walmart.com from November 4th, 2026, reaches Walmart stores December 26th and goes national in April 2027.

Read article
Read article
Freshpet raises 2026 sales outlook to 12% to 13% on 10% volume growth
Earnings
4 min read

Freshpet raises 2026 sales outlook to 12% to 13% on 10% volume growth

Freshpet raised its 2026 net sales growth outlook to 12% to 13% after third-quarter net sales rose 10.0% to $317.8M on 10.0% volume growth. Adjusted Gross Margin reached 50.0% and adjusted EBITDA was $64.5M.

Read article
View all articles